Factors associated with treatment response to etanercept in juvenile idiopathic arthritis

JAMA

Volumn 306, Issue 21, 2011, Pages 2340-2347

  Otten, Marieke H ^a   Prince, Femke H M ^a   Armbrust, Wineke ^b   Ten Cate, Rebecca ^c   Hoppenreijs, Esther P A H ^d   Twilt, Marinka ^a,c   Koopman Keemink, Yvonne ^e   Gorter, Simone L ^f   Dolman, Koert M ^g   Swart, Joost F ⁱ   Van Den Berg, J Merlijn ^h   Wulffraat, Nico M ⁱ   Van Rossum, Marion A J ^h   Van Suijlekom Smit, Lisette W A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e JULIANA CHILDREN S HOSPITAL   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h EMMA CHILDREN S HOSPITAL   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT DURATION;

EID: 83055163766     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1671     Document Type: Article

References (24)

1. Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342(11):763-769.
2. Horneff G, Schmeling H, Biedermann T, et al.; Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12): 1638-1644.
3. Lovell DJ, Reiff A, Ilowite NT, et al.; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496-1504.
4. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635-641.
5. Albers HM, Wessels JA, van der Straaten RJ, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(1):46-51.
6. van Rossum MA, van Soesbergen RM, Boers M, et al.; Dutch Juvenile Idiopathic Arthritis Study group. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007; 66(11):1518-1524.
7. Vilca I, Munitis PG, Pistorio A, et al.; Pediatric Rheumatology International Trials Organisation (PRINTO). Predictors of poor response to methotrexate in polyarticular- course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis. 2010; 69(8):1479-1483.
8. Prince FH, Ferket IS, Kamphuis S, et al. Development of a Web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl. Rheumatology (Oxford). 2008;47(9):1413-1416. 18632789.
9. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40(7):1202-1209.
10. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-2294.
11. Atzeni F, Antivalle M, Pallavicini FB, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8 (5):431-437.
12. Hetland ML, Christensen IJ, Tarp U, et al.; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22-32.
13. Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12): 1558-1565.
14. Iwamoto N, Kawakami A, Fujikawa K, et al. Prediction of DAS28-ESR remission at 6months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19(5):488-492.
15. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti- TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47(4):495-499.
16. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al.; GISEA group. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol. 2007;34(8): 1670-1673.
17. Southwood TR, Foster HE, Davidson JE, et al.; British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50(1):189-195.
18. Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of antitumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):552-557.
19. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-555.
20. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebocontrolled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann RheumDis. 2011; 70(5):747-745.
21. Swart JF, Barug D, Möhlmann M, Wulffraat NM. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010; 10(12):1743-1752.
22. BeukelmanT, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathicarthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritisandsystemicfeatures. ArthritisCareRes(Hoboken). 2011;63(4):465-482.
23. Remesal A, DE Inocencio J, Merino R, Garcia-Consuegra J. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol. 2010;37(9):1970-1971.
24. Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1228-1229.